

## SAFETY DATA SHEET

## SECTION 1: IDENTIFICATION

Product identifier used on the label:

Product Name: Palonosetron EDTA Injection

Other means of identification:

Recommended use of the chemical and restrictions on use:

Chemical manufacturer address and telephone number:

Manufacturer Name: Fresenius Kabi Austria GmbH

Address: Hafnerstrasse 36

Graz , 8055 Austria

+43.316.249.0 General Phone Number:

 $\underline{\hbox{Chemical distributor, or other responsible party Name, address, and telephone number:}\\$ 

Distributor Name: Fresenius Kabi USA, LLC Address: Three Corporate Drive Lake Zurich, Illinois 60047

General Phone Number: (847) 550-2300 Health Issues Information: (800) 551-7176

## SECTION 2: HAZARD(S) IDENTIFICATION

Classification of the chemical in accordance with CFR 1910.1200(d)(f):

GHS Pictograms:

Signal Word: WARNING!

GHS Class: Eye Irritant, Category 2. Hazard Statements: Causes serious eve irritation.

Do not breathe dust/fume/gas/mist/vapours/spray. Wash hands thoroughly after handling. Wear Precautionary Statements:

protective gloves/protective clothing/eye protection/face protection. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If skin

irritation or rash occurs: Get medical advice/attention.

 $\underline{\text{Hazards not otherwise classified that have been identified during the classification process:} \\$ 

## Citric acid

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eye: May cause eye irritation.

Ingestion: May be harmful if swallowed. May cause vomiting.

## SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

## Mixtures:

Chemical Name	CAS#	Ingredient Percent	EC Num.
Citric acid	77-92-9	7 mg/mL by weight	
Mannitol	69-65-8	202.4 mg/mL by weight	200-711-8
Palonosetron Hydrochloride	135729-62-3	0.28 mg/mL by weight	
Trisodium Citrate Dihydrate	6132-04-3	18 mg/mL by weight	

Edetate disodium dihydrate 6381-92-6 2.5 mg/mL by weight 205-358-3

Water for Injection 7732-18-5 Quantity Sufficient

## SECTION 4: FIRST AID MEASURES

#### Description of necessary measures:

Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of Eye Contact:

the eyes by separating the eyelids with fingers. Get immediate medical attention.

Skin Contact: Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing

contaminated clothing and shoes. Get medical attention if irritation develops or persists.

Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained

personnel. Seek immediate medical attention.

If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give Ingestion:

anything by mouth to an unconscious person.

Most important symptoms/effects, acute and delayed:

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

### SECTION 5: FIRE FIGHTING MEASURES

### Suitable and unsuitable extinguishing media:

Suitable Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires

involving this material.

Use extinguishing measures that are appropriate to local circumstances and the surrounding

environment.

### Specific hazards arising from the chemical:

Hazardous Combustion Byproducts:

Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

# Special protective equipment and precautions for fire-fighters:

As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) Protective Equipment:

and full protective gear.

Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to Fire Fighting Instructions:

minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.

## SECTION 6: ACCIDENTAL RELEASE MEASURES

## Personal precautions, protective equipment and emergency procedures:

Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as Personal Precautions:

listed in Section 8.

Environmental precautions:

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods and materials for containment and cleaning up:

Methods for containment: Contain spills with an inert absorbent material such as soil, sand or oil dry.

Absorb spill with inert material (e,g., dry sand or earth), then place in a chemical waste container. After Methods for cleanup:

removal, flush spill area with soap and water to remove trace residue.

## SECTION 7: HANDLING and STORAGE

# Precautions for safe handling:

When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions. Handling:

Hygiene Practices: Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

Conditions for safe storage, including any incompatibilities:

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing. Storage:

Protect from light.

Work Practices:

Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety

## SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

### **EXPOSURE GUIDELINES:**

#### Appropriate engineering controls:

Engineering Controls:

General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.

Individual protection measures:

Eve/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist. Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data.

Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection:

No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site

(http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal

protective equipment

General Hygiene Considerations:

Wash thoroughly after handling. Do not eat, drink, smoke or apply cosmetics while handling the product. Particular care in working with this product must be practiced in pharmacies and other preparation areas, during manufacture of this product, and during patient administration. Work should be performed in a designated area for working with hazardous drugs. Contaminated waste must be properly handled. Work areas must be regularly decontaminated.

## SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

### PHYSICAL AND CHEMICAL PROPERTIES:

Physical State Appearance: Liquid. Color: Clear

Odor: No information. Odor Threshold: No information. Boiling Point: Not established. Melting Point: Not established. No information. Density: Specific Gravity: No information. Specific Volume: No information.

Solubility: Soluble in most organic solvents. Soluble in water.

Vapor Density: Not established. Vapor Pressure: Not established Percent Volatile: Not established. Evaporation Point: No information.

pH: 4.5-5.5 Molecular Formula: Mixture Molecular Weight: 365.86

Viscosity: No information. Coefficient of Water/Oil No information.

Flash Point: Not established Flash Point Method: Not established. Lower Flammable/Explosive Limit: Not established. Upper Flammable/Explosive Limit: Not established. Auto Ignition Temperature: Not established. VOC Content: No information.

## SECTION 10: STABILITY and REACTIVITY

Chemical Stability:

Chemical Stability: Stable under normal temperatures and pressures.

Possibility of hazardous reactions:

Hazardous Polymerization: Not reported

Conditions To Avoid:

Conditions to Avoid: No conditions contributing to instability are known to exist for normal handling of this product.

### SECTION 11: TOXICOLOGICAL INFORMATION

#### TOXICOLOGICAL INFORMATION:

#### Palonosetron Hydrochloride:

LD50 (oral-rat): >500 mg/kg (OECD Guideline 402, GLP) (ECHA) Acute Toxicity:

Citric acid:

Not expected to produce adverse effects on fertility or development under occupational exposure conditions. Reproductive Toxicity:

Mannitol:

RTECS Number: OP2060000

Ingestion: LD50 Oral - rat - 13,500 mg/kg

**Trisodium Citrate Dihydrate:** 

Eye: No or moderate irritation in rabbits.

Skin: Dermal - Rat LD50: >2000mg/kg (OECD Guideline 402, GLP) (TS : Citric acid) (ECHA) No irritation in rabbits.

Ingestion: Oral - Rat LD50: >8000 mg/kg (TS: Sodium Citrate) (CHEMINFO)

**Edetate disodium dihydrate:** 

RTECS Number: AH4375000

Rabbit, Moderate irritation. Eye:

Skin: Dermal- Rabbit LD50: > 10000 mg/kg (ECHA)

Slight irritation.

Inhalation: Inhalation - Rat LC50:> 42 mg/L/1h (ECHA)

Ingestion: Oral - Rat LD50: 3550 mg/kg (ECHA)

Intravenous. - Mouse LD50: 645 mg/kg [Details of toxic effects not reported other than lethal dose Other Toxicological Information:

value1

Intravenous. - Rabbit LDLo: 1100 mg/kg [Behavioral - convulsions or effect on seizure threshold Behavioral - muscle contraction or spasticity Cardiac - other changes]
Intravenous. - Guinea pig LDLo: 300 mg/kg [Details of toxic effects not reported other than lethal dose

Intravenous. - Mouse TDLo: 2.1 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)] Intravenous. - Rabbit LDLo: 1.5 mg/kg [Details of toxic effects not reported other than lethal dose

Intravenous. - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)]
Subcutaneous - Rat LDLo: 3500 mg/kg [Behavioral - irritability]
Subcutaneous - Mouse LD50: 3 gm/kg [Details of toxic effects not reported other than lethal dose

value]

Subcutaneous - Guinea pig LDLo: 2160 mg/kg [Details of toxic effects not reported other than lethal

dose value1

Subcutaneous - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Skin and Appendages - dermatitis,

irritative (after systemic exposure)]
Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Effects on Embryo or Fetus - fetal death]
Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Specific Developmental Abnormalities -

musculoskeletal system]
Subcutaneous - Mouse TDLo: 2500 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity

(except death, e.g., stunted fetus)]
Subcutaneous - Mouse TDLo: 13440 mg/kg [Reproductive - Fertility - abortion]
Intraperitoneal. - Mouse LD50: 2602 mg/kg [Details of toxic effects not reported other than lethal dose

value] Intraperitoneal. - Rat LD50: 2600 mg/kg [Details of toxic effects not reported other than lethal dose

value]

Intraperitoneal. - Rat LDLo: 3.72 gm/kg [Behavioral - tremor Behavioral - convulsions or effect on seizure threshold]
Intraperitoneal. - Rat TDLo: 1710 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity

(except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system]
Intraperitoneal. - Rat TDLo: 10 gm/kg [Reproductive - Effects on Newborn - behavioral]
Intraperitoneal. - Rat Cytogenetic analysis: 2338 mg/kg

# SECTION 12: ECOLOGICAL INFORMATION

## Citric acid:

Ecotoxicity:

Ecotoxicity: No ecotoxicity data was found for the product.

Environmental Stability: No environmental information found for this product.

Trisodium Citrate Dihydrate:

Ecotoxicity:

Ecotoxicity:

Golden orfe (Leuciscus idus melanotus) LC50 (48 h) 440 mg/L (TS : Citric acid) Water flea (Ceriodaphnia sp.) EC50 (48hr) 736 mg/L (TS : Sodium Citrate) Green algae (Scenedesmus quadricauda) Toxicity Threshold (8d) 640 mg/L, NOEC (8d) 425 mg/L

## **Edetate disodium dihydrate:**

Ecotoxicity:

Ecotoxicity:

Bluegill sunfish (Lepomis macrochirus) LC50 (96hr) 5840 mg/L, Fathead minnows (Pimephales promelas) NOEC 33 d 252 mg/L Water flea (Daphnia magna) LC50 (48hr) 874 mg/L, Water flea (Daphnia pulex) NOEC (21d) 314

mg/L Marine diatom (Nitzschia sp.) EC50 (120hr) 2430 mg/L (ECHA)

## SECTION 13: DISPOSAL CONSIDERATIONS

Description of waste:

Citric acid:

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

## SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated. DOT UN Number: Not Regulated.

## SECTION 15: REGULATORY INFORMATION

Safety, health and environmental regulations specific for the product:

**Mannitol**:

EC Number: 200-711-8

**Edetate disodium dihydrate:** 

TSCA Inventory Status: Listed Canada DSL: Listed EC Number: 205-358-3

## SECTION 16: ADDITIONAL INFORMATION

**HMIS Ratings**:

HMIS Health Hazard: 1 HMIS Fire Hazard: 1 HMIS Reactivity: n HMIS Personal Protection: В

Health Hazard	1
Fire Hazard	1
Reactivity	0
Personal Protection	В

SDS Creation Date: August 15, 2018 SDS Revision Date: August 15, 2018

Copyright© 1996-2018 Enviance. All Rights Reserved.